ALLELERX THERAPEUTICS, INC.
Advancing Gene Therapy for PMM2-CDG
AlleleRx Therapeutics is developing AAV-based gene therapy for phosphomannomutase 2 deficiency (PMM2-CDG), a rare inherited disorder affecting multiple organ systems.
Building on published preclinical research, we are working to advance therapeutic development toward clinical evaluation.